These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 4061102)

  • 1. Displacement of disopyramide from human plasma proteins.
    Pedersen LE; Bonde J
    Acta Pharmacol Toxicol (Copenh); 1985 Sep; 57(3):223-6. PubMed ID: 4061102
    [No Abstract]   [Full Text] [Related]  

  • 2. Protein binding of disopyramide--displacement by mono-N-dealkyldisopyramide and variation with source of alpha-1-acid glycoprotein.
    Haughey DB; Steinberg I; Lee MH
    J Pharm Pharmacol; 1985 Apr; 37(4):285-8. PubMed ID: 2860235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Displacement of lidocaine from human plasma proteins by disopyramide.
    Bonde J; Jensen NM; Burgaard P; Angelo HR; Graudal N; Kampmann JP; Pedersen LE
    Pharmacol Toxicol; 1987 Feb; 60(2):151-5. PubMed ID: 3575249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma protein binding of disopyramide by equilibrium dialysis and ultrafiltration.
    David BM; Tjokrosetio R; Ilett KF
    Ther Drug Monit; 1983; 5(1):81-6. PubMed ID: 6845403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of serum protein binding on hepatic clearance of S-disopyramide in the rabbit.
    Huang JD; Oie S
    J Pharm Pharmacol; 1985 Jul; 37(7):471-5. PubMed ID: 2863349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics and protein binding of disopyramide in pigs.
    Pedersen LE; Hermansen K; Olesen HP; Rasmussen SN
    Acta Pharmacol Toxicol (Copenh); 1986 Apr; 58(4):282-8. PubMed ID: 3716823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental evidence for concentration-dependent plasma protein binding effects on the apparent half-lives of restrictively cleared drugs.
    Lima JJ
    J Pharm Sci; 1983 Apr; 72(4):461-2. PubMed ID: 6864491
    [No Abstract]   [Full Text] [Related]  

  • 8. Binding of disopyramide to alpha 1-acid glycoprotein in plasma measured by competitive equilibrium dialysis.
    Norris RL; Ahokas JT; Ravenscroft PJ; Henry M
    J Pharm Sci; 1984 Jun; 73(6):824-6. PubMed ID: 6737271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereoselective binding of disopyramide to plasma proteins.
    Valdivieso L; Giacomini KM; Nelson WL; Pershe R; Blaschke TF
    Pharm Res; 1988 May; 5(5):316-8. PubMed ID: 3244643
    [No Abstract]   [Full Text] [Related]  

  • 10. Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.
    Lima JJ; Boudoulas H; Blanford M
    J Pharmacol Exp Ther; 1981 Dec; 219(3):741-7. PubMed ID: 7299695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.
    Lima JJ; Haughey DB; Leier CV
    J Pharmacokinet Biopharm; 1984 Jun; 12(3):289-313. PubMed ID: 6502472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor.
    Kiriyama A; Nishiura T; Ishino M; Yamamoto Y; Ogita I; Kiso Y; Takada K
    Biopharm Drug Dispos; 1996 Dec; 17(9):739-51. PubMed ID: 8968527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.
    Giacomini KM; Swezey SE; Turner-Tamiyasu K; Blaschke TF
    J Pharmacokinet Biopharm; 1982 Feb; 10(1):1-14. PubMed ID: 7069575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effect of free fatty acids on plasma protein binding of disopyramide in haemodialysis patients.
    Horiuchi T; Johno I; Hasegawa T; Kitazawa S; Goto M; Hata T
    Eur J Clin Pharmacol; 1989; 36(2):175-80. PubMed ID: 2721542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients.
    Haughey DB; Kraft CJ; Matzke GR; Keane WF; Halstenson CE
    Am J Nephrol; 1985; 5(1):35-9. PubMed ID: 3881959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative binding of disopyramide phosphate and quinidine sulfate to human plasma proteins.
    Chien YW; Lambert HJ; Karim A
    J Pharm Sci; 1974 Dec; 63(12):1877-9. PubMed ID: 4449018
    [No Abstract]   [Full Text] [Related]  

  • 17. Enantioselective binding of propranolol, disopyramide, and verapamil to human alpha(1)-acid glycoprotein.
    Hanada K; Ohta T; Hirai M; Arai M; Ogata H
    J Pharm Sci; 2000 Jun; 89(6):751-7. PubMed ID: 10824133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of disopyramide.
    Karim A; Nissen C; Azarnoff DL
    J Pharmacokinet Biopharm; 1982 Oct; 10(5):465-94. PubMed ID: 6762414
    [No Abstract]   [Full Text] [Related]  

  • 19. Stereoselective pharmacokinetics of disopyramide enantiomers in man.
    Lima JJ; Boudoulas H; Shields BJ
    Drug Metab Dispos; 1985; 13(5):572-7. PubMed ID: 2865105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of protein binding on disopyramide clearance.
    Bryson SM; Lawrence JR; Steele WH; Campbell BC; Elliott HL; Sumner DJ
    Eur J Clin Pharmacol; 1982; 23(5):453-6. PubMed ID: 7151851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.